Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190

Similar articles for PubMed (Select 23235363)

1.

The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.

Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B.

Kidney Blood Press Res. 2012;36(1):335-43. doi: 10.1159/000343391. Epub 2012 Dec 12.

PMID:
23235363
2.

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.

Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18.

PMID:
18423812
3.
4.

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.

Hypertens Res. 2012 Aug;35(8):874-81. doi: 10.1038/hr.2012.45. Epub 2012 May 17.

PMID:
22592665
5.

Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease.

Lizakowski S, Tylicki L, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B.

Pol Arch Med Wewn. 2013;123(5):221-7. Epub 2013 Apr 25.

6.

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators.

Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. doi: 10.1093/ndt/gfn230. Epub 2008 May 1.

7.

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.

Mavrakanas TA, Gariani K, Martin PY.

Eur J Intern Med. 2014 Feb;25(2):173-6. doi: 10.1016/j.ejim.2013.11.007. Epub 2013 Dec 4. Review.

PMID:
24315413
8.

AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.

Fraune C, Lange S, Krebs C, Hölzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelds IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G, Wenzel UO.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1037-48. doi: 10.1152/ajprenal.00672.2011. Epub 2012 Jul 11.

9.

Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.

Tylicki L, Renke M, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.

Scand J Urol Nephrol. 2008;42(4):381-8. doi: 10.1080/00365590801905943.

PMID:
19230172
10.

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.

Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K.

Hypertension. 2002 Aug;40(2):117-23.

11.

Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.

Abe M, Suzuki H, Okada K, Maruyama N, Inoshita A, Baba S, Takashima H, Soma M.

Heart Vessels. 2013 Jul;28(4):442-52. doi: 10.1007/s00380-012-0260-7. Epub 2012 May 23.

PMID:
22618635
12.

Direct renin inhibition--a promising strategy for renal protection?

Lizakowski S, Tylicki L, Rutkowski B.

Med Sci Monit. 2013 Jun 12;19:451-7. doi: 10.12659/MSM.883949. Review.

13.

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.

Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL.

Am J Hypertens. 2013 Mar;26(3):424-41. doi: 10.1093/ajh/hps038. Epub 2013 Jan 7.

14.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
15.

[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].

Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.

Nefrologia. 2009;29(5):421-9. doi: 10.3265/Nefrologia.2009.29.5.5448.en.full. Spanish.

16.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

PMID:
25399731
17.

Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.

Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B.

Int Urol Nephrol. 2012 Dec;44(6):1763-70.

18.

Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.

Doulton TW, MacGregor GA.

J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):185-9. doi: 10.1177/1470320309342733. Epub 2009 Jul 17.

PMID:
19617273
19.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

20.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk